{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T13:29:51Z","timestamp":1744118991581,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-021-00419-1","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T21:23:32Z","timestamp":1612905812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0857-176X","authenticated-orcid":false,"given":"Elisabet E.","family":"Manasanch","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3429-5826","authenticated-orcid":false,"given":"Chutima","family":"Kunacheewa","sequence":"additional","affiliation":[]},{"given":"Catherine M.","family":"Claussen","sequence":"additional","affiliation":[]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[]},{"given":"Jill","family":"Gunther","sequence":"additional","affiliation":[]},{"given":"Chelsea C.","family":"Pinnix","sequence":"additional","affiliation":[]},{"given":"Bouthaina S.","family":"Dabaja","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-3466","authenticated-orcid":false,"given":"Behrang","family":"Amini","sequence":"additional","affiliation":[]},{"given":"Raymond","family":"Alexanian","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-4129","authenticated-orcid":false,"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[]},{"given":"Wenli","family":"Dong","sequence":"additional","affiliation":[]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[]},{"given":"Donna M.","family":"Weber","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"419_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-118","volume":"6","author":"D Knobel","year":"2006","unstructured":"Knobel, D. et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer 6, 118 (2006).","journal-title":"BMC Cancer"},{"key":"419_CR2","first-page":"JCO1901740","volume":"38","author":"S Lonial","year":"2019","unstructured":"Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, JCO1901740 (2019).","journal-title":"J. Clin. Oncol."},{"key":"419_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 (2013).","journal-title":"N. Engl. J. Med."},{"key":"419_CR4","doi-asserted-by":"crossref","unstructured":"Manasanch E. et al. A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM). Blood abs 3116 Presented at ASH 2019 Annual Meeting (American Society Of Hematology, Orlando, FL. 2019).","DOI":"10.1182\/blood-2019-123205"},{"key":"419_CR5","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1182\/bloodadvances.2019000300","volume":"3","author":"EE Manasanch","year":"2019","unstructured":"Manasanch, E. E. et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 3, 2400\u20132408 (2019).","journal-title":"Blood Adv."},{"key":"419_CR6","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"419_CR7","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1182\/blood-2014-04-567909","volume":"124","author":"B Paiva","year":"2014","unstructured":"Paiva, B. et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood 124, 1300\u20131303 (2014).","journal-title":"Blood"},{"key":"419_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/ejh.12907","volume":"99","author":"H Nahi","year":"2017","unstructured":"Nahi, H. et al. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. Eur. J. Haematol. 99, 216\u2013222 (2017).","journal-title":"Eur. J. Haematol."},{"key":"419_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijrobp.2005.06.039","volume":"64","author":"M Ozsahin","year":"2006","unstructured":"Ozsahin, M. et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int. J. Radiat. Oncol. Biol. Phys. 64, 210\u2013217 (2006).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"419_CR10","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1182\/blood-2006-04-015784","volume":"108","author":"D Dingli","year":"2006","unstructured":"Dingli, D. et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 108, 1979\u20131983 (2006).","journal-title":"Blood."},{"key":"419_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.1992.10.4.587","volume":"10","author":"MA Dimopoulos","year":"1992","unstructured":"Dimopoulos, M. A., Goldstein, J., Fuller, L., Delasalle, K. & Alexanian, R. Curability of solitary bone plasmacytoma. J. Clin. Oncol. 10, 587\u2013590 (1992).","journal-title":"J. Clin. Oncol."},{"key":"419_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/1097-0142(19920315)69:6<1513::AID-CNCR2820690633>3.0.CO;2-X","volume":"69","author":"J Holland","year":"1992","unstructured":"Holland, J., Trenkner, D. A., Wasserman, T. H. & Fineberg, B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 69, 1513\u20131517 (1992).","journal-title":"Cancer."},{"key":"419_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/bjc.1995.26","volume":"71","author":"LY Shih","year":"1995","unstructured":"Shih, L. Y., Dunn, P., Leung, W. M., Chen, W. J. & Wang, P. N. Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br. J. Cancer 71, 128\u2013133 (1995).","journal-title":"Br. J. Cancer"},{"key":"419_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/(SICI)1099-1069(199609)14:3<111::AID-HON575>3.0.CO;2-G","volume":"14","author":"A Aviles","year":"1996","unstructured":"Aviles, A., Huerta-Guzman, J., Delgado, S., Fernandez, A. & Diaz-Maqueo, J. C. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol. Oncol. 14, 111\u2013117 (1996).","journal-title":"Hematol. Oncol."},{"key":"419_CR15","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1080\/10428194.2019.1605067","volume":"60","author":"K Mheidly","year":"2019","unstructured":"Mheidly, K. et al. New insights in the treatment of patients with solitary bone plasmacytoma. Leuk. Lymphoma 60, 2810\u20132813, https:\/\/doi.org\/10.1080\/10428194.2019.1605067 (2019).","journal-title":"Leuk. Lymphoma"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00419-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:39:44Z","timestamp":1669909184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00419-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00419-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"type":"electronic","value":"2044-5385"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"30 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.M. has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, Merck; consultant fees from Takeda, Celgene, Sanofi, Janssen and Adaptive Biotechnologies. C.K. reports no conflicts of interest. C.M.C. reports no conflicts of interest. H.L. has received consulting fees from Adaptive Biotechnologies, Celgene, Pimera, and Takeda, and research support from Amgen, Daiichi Sankyo, Janssen, and Takeda. S.T. reports no conflicts of interest. J.G. reports no conflicts of interest. C.C.P. reports no conflicts of interest. B.S.D. reports no conflicts of interest. B.A. reports no conflicts of interest. R.A. reports no conflicts of interest. R.O. has received consulting fees from Amgen, Bristol-Myers-Squibb, Celgene, GSK Biologicals, Ionis Pharmaceuticals, Janssen, Juno Therapeutics, Kite Pharma, Legend Biotech, Molecular Partners, Sanofi, Servier, and Takeda and research support from BioTheryX. W.D. reports no conflicts of interest. L.F. reports no conflicts of interest. D.W. reports no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"17"}}